


Levemopamil hydrochloride

Cat. No.:	HY-113643
CAS No.:	101238-54-4
Molecular Formula:	C ₂₃ H ₃₁ ClN ₂
Molecular Weight:	370.96
Target:	Calcium Channel; 5-HT Receptor
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Levemopamil hydrochloride is a blood-brain barrier penetrable calcium channel blocker and a 5-HT ₂ antagonist. Levemopamil hydrochloride can be used for temporary occlusion and neurological disease research ^[1] .								
In Vivo	<p>Levemopamil hydrochloride (30 mg/kg; i.p., once) regulates bilateral damping of carotid arteries (BCCA) process and reduces spatial memory deficits induced by cerebral oligemia of rats^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Han-Wistar rats with bilateral damping of carotid arteries (BCCA)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 30 mg/kg, once</td> </tr> <tr> <td>Result:</td> <td>Showed no effect on GABA or ACh content in either BCCA or sham-operated control rats. Significantly increased swimming speed of BCCA rats in swimming test. Prevented the increasing of escape latency to reach the hidden platform.</td> </tr> </table>	Animal Model:	Male Han-Wistar rats with bilateral damping of carotid arteries (BCCA) ^[1]	Dosage:	30 mg/kg	Administration:	Intraperitoneal injection; 30 mg/kg, once	Result:	Showed no effect on GABA or ACh content in either BCCA or sham-operated control rats. Significantly increased swimming speed of BCCA rats in swimming test. Prevented the increasing of escape latency to reach the hidden platform.
Animal Model:	Male Han-Wistar rats with bilateral damping of carotid arteries (BCCA) ^[1]								
Dosage:	30 mg/kg								
Administration:	Intraperitoneal injection; 30 mg/kg, once								
Result:	Showed no effect on GABA or ACh content in either BCCA or sham-operated control rats. Significantly increased swimming speed of BCCA rats in swimming test. Prevented the increasing of escape latency to reach the hidden platform.								

REFERENCES

[1]. Heim C, et al. Levemopamil injection after cerebral oligemia reduces spatial memory deficits in rats. *Pharmacol Biochem Behav.* 1994 Jul;48(3):613-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA